



CSD/SE/2026-27
Date: May 29, 2026

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400001

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 read with Schedule III of the SEBI (LODR) Regulations, 2015 and SEBI Circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 this is to hereby inform that the Company received Rectification order for assessment year 2020-21, from Income Tax Department. Details are as given in **Annexure - A.**

This is for your information and record.

Thanking you.

For **Suven Life Sciences Limited**

K. Sangeetha Laxmi
Company Secretary & Compliance officer

Encl:- as above

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com

Annexure – A

Details as per SEBI Circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 regarding Action(s) taken or orders passed by any regulatory/ statutory/ enforcement authority or judicial body

Name of the authority	Income Tax Department, Kondapur, Hyderabad
Nature and details of the action(s) taken or order(s) passed	Rectification order u/s 154 of Income Tax Act
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Email communication dated 28 th May, 2026
Details of the violation(s)/ contravention(s) committed or alleged to be committed	Rectification order u/s 154 of the Income Tax Act, 1961 ('Act'), for the reason that weighted deduction claimed U/s. 35 (2AB) with respect to the expenditure incurred by the company on Research & Development activities, was disallowed for want of approval from Department of Scientific and Industrial and Research (DSIR) in Form No. 3CL, in the order passed under section 143(3) of the Act. In this connection, the Company has already given a detailed reply stating reasons to drop the notice considering both legal aspects and merits of the case. However, without considering the contentions of the Company the Assessing Officer (AO/Authority) has passed order u/s 154 of the Act
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	The Company is preferring an appeal to appellate authority against the Rectification order received from authority and Company does not foresee any material impact of the same on financials, operations or other activities of the Company

Suven Life Sciences Limited